Biblio

Export 1121 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is T  [Clear All Filters]
Journal Article
L. Trojano and Gainotti, G., “Drawing Disorders in Alzheimer's Disease and Other Forms of Dementia.”, J Alzheimers Dis, vol. 53, no. 1, pp. 31-52, 2016.
G. Manassero, Guglielmotto, M., Monteleone, D., Vasciaveo, V., Butenko, O., Tamagno, E., Arancio, O., and Tabaton, M., “Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice.”, J Alzheimers Dis, vol. 59, no. 2, pp. 743-751, 2017.
G. Manassero, Guglielmotto, M., Monteleone, D., Vasciaveo, V., Butenko, O., Tamagno, E., Arancio, O., and Tabaton, M., “Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice.”, J Alzheimers Dis, vol. 59, no. 2, pp. 743-751, 2017.
L. Florek, Tiepolt, S., Schroeter, M. L., Berrouschot, J., Saur, D., Hesse, S., Jochimsen, T., Luthardt, J., Sattler, B., Patt, M., Hoffmann, K. - T., Villringer, A., Classen, J., Gertz, H. - J., Sabri, O., and Barthel, H., “Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1105-1116, 2018.
Y. Pan, Liu, R., Terpstra, E., Wang, Y., Qiao, F., Wang, J., Tong, Y., and Pan, B., “Dysregulation and diagnostic potential of microRNA in Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 1-12, 2016.
Y. Pan, Liu, R., Terpstra, E., Wang, Y., Qiao, F., Wang, J., Tong, Y., and Pan, B., “Dysregulation and diagnostic potential of microRNA in Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 1-12, 2016.
C. Lanzillotta, Tramutola, A., Meier, S., Schmitt, F., Barone, E., Perluigi, M., Di Domenico, F., and Abisambra, J. F., “Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.”, J Alzheimers Dis, vol. 62, no. 1, pp. 347-359, 2018.
A. Tort-Merino, Valech, N., Peñaloza, C., Grönholm-Nyman, P., León, M., Olives, J., Estanga, A., Ecay-Torres, M., Fortea, J., Martínez-Lage, P., Molinuevo, J. L., Laine, M., Rodríguez-Fornells, A., and Rami, L., “Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1.”, J Alzheimers Dis, vol. 58, no. 3, pp. 855-870, 2017.
K. Kantarci, Lowe, V. J., Lesnick, T. G., Tosakulwong, N., Bailey, K. R., Fields, J. A., Shuster, L. T., Zuk, S. M., Senjem, M. L., Mielke, M. M., Gleason, C., Jack, C. R., Rocca, W. A., and Miller, V. M., “Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.”, J Alzheimers Dis, vol. 53, no. 2, pp. 547-56, 2016.
B. Gurel, Cansev, M., Sevinc, C., Kelestemur, S., Ocalan, B., Cakir, A., Aydin, S., Kahveci, N., Ozansoy, M., Taskapilioglu, O., Ulus, I. Hakki, Başar, M. Karayel, Sahin, B., Tuzuner, M. Bora, and Baykal, A. Tarik, “Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1399-1410, 2018.
B. Gurel, Cansev, M., Sevinc, C., Kelestemur, S., Ocalan, B., Cakir, A., Aydin, S., Kahveci, N., Ozansoy, M., Taskapilioglu, O., Ulus, I. Hakki, Başar, M. Karayel, Sahin, B., Tuzuner, M. Bora, and Baykal, A. Tarik, “Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1399-1410, 2018.
S. M. de la Monte, Tong, M., Daiello, L. A., and Ott, B. R., “Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways.”, J Alzheimers Dis, vol. 68, no. 2, pp. 657-668, 2019.
B. Michalowsky, Thyrian, J. René, Eichler, T., Hertel, J., Wucherer, D., Flessa, S., and Hoffmann, W., “Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.”, J Alzheimers Dis, vol. 50, no. 1, pp. 47-59, 2016.
S. Ikeda, Mimura, M., Ikeda, M., Wada-Isoe, K., Azuma, M., Inoue, S., and Tomita, K., “Economic Burden of Alzheimer's Disease Dementia in Japan.”, J Alzheimers Dis, vol. 81, no. 1, pp. 309-319, 2021.
L. Er Simmatis, Russo, E. E., Steininger, T., Riddell, H., Chen, E., Chiu, Q., Lin, M., Oh, D., Taheri, P., Harmsen, I. E., and Samuel, N., “EEG biomarkers for Alzheimer's disease: A novel automated pipeline for detecting and monitoring disease progression.”, J Alzheimers Dis, p. 13872877251327754, 2025.
L. Bonanni, Franciotti, R., Nobili, F., Kramberger, M. G., Taylor, J. - P., Garcia-Ptacek, S., N Falasca, W., Famá, F., Cromarty, R., Onofrj, M., and Aarsland, D., “EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1649-1657, 2016.
T. Hisatsune, Kaneko, J., Kurashige, H., Cao, Y., Satsu, H., Totsuka, M., Katakura, Y., Imabayashi, E., and Matsuda, H., “Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People.”, J Alzheimers Dis, vol. 50, no. 1, pp. 149-59, 2016.
J. Morris K, Uy, R. Adeline Z., Vidoni, E. D., Wilkins, H. M., Archer, A. E., Thyfault, J. P., Miles, J. M., and Burns, J. M., “Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1129-1135, 2017.
M. Wada, Noda, Y., Shinagawa, S., Chung, J. Ku, Sawada, K., Ogyu, K., Tarumi, R., Tsugawa, S., Miyazaki, T., Yamagata, B., Graff-Guerrero, A., Mimura, M., and Nakajima, S., “Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 63, no. 2, pp. 861-869, 2018.
M. Wada, Noda, Y., Shinagawa, S., Chung, J. Ku, Sawada, K., Ogyu, K., Tarumi, R., Tsugawa, S., Miyazaki, T., Yamagata, B., Graff-Guerrero, A., Mimura, M., and Nakajima, S., “Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 63, no. 2, pp. 861-869, 2018.
D. Asaoka, Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., Ichimiya, Y., Koido, S., Ohno, K., Bernier, F., Katsumata, N., Nagahara, A., Arai, H., Ohkusa, T., and Sato, N., “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
J. Toombs, Foiani, M. S., Paterson, R. W., Heslegrave, A., Wray, S., Schott, J. M., Fox, N. C., Lunn, M. P., Blennow, K., and Zetterberg, H., “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
A. Carotenuto, Rea, R., Traini, E., Fasanaro, A. Maria, Ricci, G., Manzo, V., and Amenta, F., “The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.”, J Alzheimers Dis, vol. 56, no. 2, pp. 805-815, 2017.
Y. Tripodis, Alosco, M. L., Zirogiannis, N., Gavett, B. E., Chaisson, C., Martin, B., McClean, M. D., Mez, J., Kowall, N., and Stern, R. A., “The Effect of Traumatic Brain Injury History with Loss of Consciousness on Rate of Cognitive Decline Among Older Adults with Normal Cognition and Alzheimer's Disease Dementia.”, J Alzheimers Dis, vol. 59, no. 1, pp. 251-263, 2017.
A. A. Diaz Baquero, Franco-Martín, M. A., Vidales, E. Parra, Toribio-Guzmán, J. Miguel, Bueno-Aguado, Y., Abad, F. Martínez, Bartolomé, M. V. Perea, Asl, A. Mahmoudi, and van der Roest, H. G., “The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 711-727, 2022.

Pages